AI Multi-Horizon Analysis
No intraday price-action, volume or order-flow data available; directionless on minutes horizon.
Near upper end of multi-month range after earnings surprise; insider selling and cash-burn concerns cap upside while positive margins provide support. Remains news-flow driven.
Multi-year downtrend from pandemic highs continues; mRNA platform and pipeline offer upside but persistent negative FCF, equity erosion, dilution and revenue seasonality weigh on valuation sustainability.
Q3 2026 showed first positive operating and net margins in periods reviewed, yet this is overshadowed by accelerating cash burn, ongoing equity erosion, heavy insider net selling, and persistent revenue volatility. Technical posture is neutral-to-cautious within a longer-term downtrend; binary pipeline catalysts dominate.
Detailed AI Fundamental Analysis
Business Snapshot
Moderna, Inc. (MRNA) is a biotechnology company focused on messenger RNA (mRNA) therapeutics and vaccines. The company commercializes products in the respiratory vaccine space while maintaining a broad pipeline in oncology, rare diseases, and other infectious diseases. As of the latest data, Moderna employs approximately 4,700 people, has 404 million shares outstanding, and carries a market capitalization of roughly $101.5 billion. The stock trades on NASDAQ as common shares (CS) and remains a high-volatility name driven by clinical, regulatory, and commercial catalysts in the mRNA platform.
Financial Trends
Revenue shows extreme volatility and no clear recovery trend: Q3 2026 revenue reached $1.313 billion versus $145 million in Q2 2026 (+805% QoQ) but remains well below the $1.944 billion reported in Q4 2025. Over the four periods, revenue has declined sharply from the year-end 2025 peak, with Q3 2026 still 32% lower than Q4 2025.
Operating and net margins remain deeply negative in three of the four periods but inflected sharply in Q3 2026. Operating margin improved from -562% in Q2 2026 to +9.9% in Q3 2026; net margin moved from -539% to +12.3%. However, full-year trajectory is still negative: Q3 2026 net margin of +12.3% compares to -145% in Q4 2025.
Free cash flow (FCF) has deteriorated markedly. Cash burn accelerated from -$692 million in Q1 2026 to -$1.255 billion in Q2 2026 to -$2.861 billion in Q3 2026. Compared with four periods ago (Q4 2025 FCF of -$2.065 billion), the latest quarter shows 38% worse cash burn.
Balance-sheet strength is mixed. Total assets rose 23% from Q2 2026 ($10.96B) to Q3 2026 ($13.47B), but shareholders’ equity has declined steadily from $8.65B in Q4 2025 to $6.84B in Q3 2026 (-21% over four periods). Cash & equivalents have fallen every quarter, dropping from $2.595B at year-end 2025 to $1.195B in Q3 2026 (-54%). Total liabilities have surged 80% from $3.69B in Q4 2025 to $6.63B in Q3 2026, driven largely by current liabilities and new financing activity. Debt/Equity improved to zero in Q3 after earlier modest leverage, but this reflects equity erosion more than debt reduction. Shares outstanding have increased 2.5% over the last four quarters, indicating ongoing dilution.
Financial Health
The latest Q3 2026 period shows an apparent operating inflection with positive operating income ($130M) and net income ($162M), yet this sits atop accelerating cash burn of $2.86B and a 54% drawdown in cash reserves over the past year. Liquidity remains adequate with a current ratio of 3.62 and $5.32B in working capital, but the sharp sequential rise in total liabilities (+58% QoQ) and continued erosion of retained earnings and shareholders’ equity signal weakening balance-sheet quality. The company is burning cash far faster than it is generating profits, relying on financing activities ($2.78B inflow in Q3) to sustain operations. Trend-wise, the single profitable quarter does not yet offset four consecutive periods of heavy losses and negative FCF; forward sustainability hinges on revenue stabilization and containment of operating expenses that remain elevated at $1.18B.
Insider Activity
Insider sentiment over the reported window is Neutral with a net score of -8. Aggregate activity shows clear net selling pressure: $36.96M in sells across 38 transactions versus only $4.46M in buys across 6 transactions, for a net outflow of $32.5M. The most recent Form 4 filings for Stephen Hoge (October 2026) illustrate a common insider pattern of exercising options (two buys totaling ~$1.867M at a strike of $12.21) followed by immediate open-market sales of roughly $17.0M at prices between $213.47 and $220.72. This results in substantial net profit-taking despite the reported “buy” line items. Overall, the volume and consistency of selling outweigh isolated option exercises, pointing to cautious or opportunistic positioning by insiders at current price levels near $280.
Multi-Timeframe Technical Context
With the active timeframe labeled “fundamental” and session high/low data unavailable, price action context is limited to the current print of $279.71. On an ultra-short (minute) horizon the lack of intraday candle or indicator data precludes momentum or order-flow conclusions. On the short-term (hourly to daily) horizon the stock trades near the upper end of its recent multi-month range, consistent with a volatile biotech name that has recovered from deeper 2026 lows but remains well below prior highs. Long-term (weekly to monthly) the chart reflects a multi-year downtrend from pandemic-era peaks, now attempting to establish support above $200–$250 while facing overhead supply from 2025–2026 distribution levels. Absent explicit moving-average, RSI, or volume data, the technical picture is neutral-to-cautious, with price largely driven by binary clinical or commercial news flow rather than steady trend.
Bull / Bear Cases
Short-term Bull Case (hours to days): Positive Q3 earnings surprise and first profitable quarter in the reported series could catalyze a relief rally if accompanied by upward guidance or pipeline updates. Any positive respiratory vaccine demand signals or accelerated regulatory milestones may drive momentum buying toward $300–$320 resistance.
Short-term Bear Case (hours to days): Continued heavy insider selling, accelerating cash burn, and a still-negative annual earnings trajectory may trigger profit-taking or short covering reversals. Failure to hold $260 support on any negative clinical readout or disappointing forward commentary would likely retest lower recent lows.
Long-term Bull Case (weeks to months): Successful commercialization of next-generation COVID/flu combination vaccines, positive Phase 3 oncology data, or meaningful partnership revenue could stabilize top-line growth, improve FCF, and rebuild equity. If operating margins sustain positive territory and cash burn moderates, the mRNA platform’s broad pipeline may justify current valuation and support a re-rating higher.
Long-term Bear Case (weeks to months): Persistent revenue volatility, ongoing negative FCF exceeding $5B annualized, continued equity erosion, and rising liabilities could force additional dilution or debt issuance. If new product launches disappoint or competition erodes market share, the company risks a prolonged downtrend and potential need for strategic restructuring.
Key Levels & Triggers
- Immediate Support: $260 (psychological and recent swing low); $230–$240 (multi-month base).
- Immediate Resistance: $300 (round number and prior supply zone); $320–$340 (next major overhead from 2026 distribution).
- Positive Triggers: Sustained revenue growth above $1B/quarter, positive FCF inflection, successful Phase 3 readouts, or insider buying acceleration.
- Negative Triggers: Cash balance dropping below $1B, further equity erosion below $6B, renewed negative EPS surprises, or material adverse clinical/regulatory events.
- Risk Note: Extreme revenue seasonality and binary pipeline events make traditional technical levels secondary to news flow; position sizing should reflect high volatility.